Under-reporting of Validation Efforts for Health Economic Models Persists Despite the Availability of Validation Tools: A Systematic Review

被引:0
作者
Abraham, Katharina [1 ]
Ramos, Isaac Corro [2 ]
Braal, C. Louwrens [3 ]
Feenstra, Talitha [4 ,5 ]
Kleijburg, Anne [6 ,7 ]
van Voorn, George A. K. [8 ]
Uyl-de Groot, Carin [9 ]
机构
[1] Erasmus Univ Rotterdam EUR, Erasmus Sch Hlth Policy & Management, Rotterdam, South Holland, Netherlands
[2] EUR, Inst Med Technol Assessment iMTA, Rotterdam, South Holland, Netherlands
[3] Erasmus Univ MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[4] Univ Groningen, Groningen Res Inst Pharm, Fac Sci & Engn, Groningen, Netherlands
[5] Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands
[6] Maastricht Univ, CAPHRI Care & Publ Hlth Res Inst, Dept Hlth Serv Res, Maastricht, Netherlands
[7] Trimbos Inst, Netherlands Inst Mental Hlth & Addict, Ctr Econ Evaluat & Machine Learning, Utrecht, Netherlands
[8] Wageningen Univ & Res, Appl Math & Stat Biometr, Wageningen, Netherlands
[9] EUR, Erasmus Sch Hlth Policy & Management, Rotterdam, South Holland, Netherlands
关键词
EARLY BREAST-CANCER; COST-EFFECTIVENESS ANALYSIS; ADJUVANT TRASTUZUMAB; ENDOCRINE THERAPY; RECONSTRUCTION; HER2;
D O I
10.1007/s40273-025-01491-2
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objective In this study we aimed to identify possible changes over time in validation efforts and the way in which they are reported for model-based health economic (HE) evaluations, given the introduction of several new validation tools and methods in the past decade. Methods A systematic review was conducted using PubMed and Embase on published HE models for early breast cancer (EBC) for the period 2016 to 2024. AdViSHE-consisting of four validation categories that cover the main HE model aspects-was utilized to systematically evaluate the reported evaluation efforts. The percentage of studies reporting validation per category was compared with the review by de Boer et al. that covers the years 2008 to 2015. Results Of the 2199 records, 78 studies fulfilled the eligibility criteria. Reported validation efforts did not significantly improve compared with the previous period, except for the validation of input data by experts. Reporting on the validation of the conceptual model remained low with around 10% of the studies providing validation. Validation of the computerized model and validation against outcomes using alternative input data were the most underreported validation categories with < 4% of the studies. The validation of model outcomes, specifically cross validity and the comparison with empirical data, remained the most reported categories in this review also, with 52% and 36%, respectively. When validation efforts were reported, this was done in a non-systematic manner, and the tests and results were rarely detailed. Conclusion Overall reporting of validation efforts for model-based HE evaluations in the past decade did not significantly change compared with the previous decade.
引用
收藏
页数:10
相关论文
共 53 条
  • [1] Adibi A, 2022, Arxiv, DOI [arXiv:2202.08358, 10.48550/arXiv.2202.08358, DOI 10.48550/ARXIV.2202.08358]
  • [2] Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa
    Alshreef, Abualbishr
    MacQuilkan, Kim
    Dawkins, Bryony
    Riddin, Jane
    Ward, Sue
    Meads, David
    Taylor, Matthew
    Dixon, Simon
    Culyer, Anthony J.
    Ruiz, Francis
    Chalkidou, Kalipso
    Edoka, Ijeoma
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2019, 19 : 65 - 74
  • [3] [Anonymous], Your personal research assistant
  • [4] [Anonymous], 2021, Rayyan-Intelligent Systematic Review-Rayyan
  • [5] A cost-utility analysis comparing large volume displacement oncoplastic surgery to mastectomy with single stage implant reconstruction in the treatment of breast cancer
    Asban, Ammar
    Homsy, Christopher
    Chen, Lilian
    Fisher, Carla
    Losken, Albert
    Chatterjee, Abhishek
    [J]. BREAST, 2018, 41 : 159 - 164
  • [6] Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil
    Botelho, Carlos Henrique
    Estevez-Diz, Maria Del Pilar
    Campolina, Alessandro Goncalves
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2022, 22 (01) : 63 - 72
  • [7] Therapeutic Drug Monitoring-Guided Adjuvant Tamoxifen Dosing in Patients with Early Breast Cancer: A Cost-Effectiveness Analysis from the Prospective TOTAM Trial
    Braal, C. Louwrens
    Kleijburg, Anne
    Jager, Agnes
    Koolen, Stijn L. W.
    Mathijssen, Ron H. J.
    Ramos, Isaac Corro
    Wetzelaer, Pim
    Uyl-de Groot, Carin A.
    [J]. CLINICAL DRUG INVESTIGATION, 2022, 42 (02) : 163 - 175
  • [8] Cost-effectiveness of Canal Wall-Up vs Canal Wall-Down Mastoidectomy: A Modeling Study
    Bu, Daniel D.
    Schwam, Zachary G.
    Kaul, Vivian F.
    Wong, Kevin
    Fan, Caleb
    Wanna, George B.
    Cosetti, Maura K.
    Perez, Enrique
    [J]. OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 2022, 167 (03) : 552 - 559
  • [9] TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility
    Buyukkaramikli, Nasuh C.
    Rutten-van Molken, Maureen P. M. H.
    Severens, Johan L.
    Al, Maiwenn
    [J]. PHARMACOECONOMICS, 2019, 37 (11) : 1391 - 1408
  • [10] Questionnaire to Assess Relevance and Credibility of Modeling Studies for Informing Health Care Decision Making: An ISPOR-AMCP-NPC Good Practice Task Force Report
    Caro, J. Jaime
    Eddy, David M.
    Kan, Hong
    Kaltz, Cheryl
    Patel, Bimal
    Eldessouki, Randa
    Briggs, Andrew H.
    [J]. VALUE IN HEALTH, 2014, 17 (02) : 174 - 182